Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis
BACKGROUND Cancer patients produce autoantibodies to self‐proteins called tumor‐associated antigens (TAA). These autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. This study was designed to identify TAA in prostate cancer (PCa). METHODS Ser...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2005-01, Vol.62 (1), p.14-26 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 26 |
|---|---|
| container_issue | 1 |
| container_start_page | 14 |
| container_title | The Prostate |
| container_volume | 62 |
| creator | Daniels, Tracy Zhang, Jianying Gutierrez, Israel Elliot, Max L. Yamada, Brian Heeb, Mary Jo Sheets, Shaun M. Wu, Xiwei Casiano, Carlos A. |
| description | BACKGROUND
Cancer patients produce autoantibodies to self‐proteins called tumor‐associated antigens (TAA). These autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. This study was designed to identify TAA in prostate cancer (PCa).
METHODS
Serum autoantibodies to the survival protein lens epithelium‐derived growth factor p75 (LEDGF/p75) were detected by immunofluorescence microscopy, ELISA, and immunoblotting. Expression of LEDGF/p75 in prostate cells and tumors was evaluated by immunoblotting or immunohistochemistry. Apoptotic cleavage of LEDGF/p75 was detected by immunoblotting.
RESULTS
Anti‐LEDGF/p75 autoantibodies were detected by ELISA in 18.4% of PCa patients and 5.5% of matched controls (P |
| doi_str_mv | 10.1002/pros.20112 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67255299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67255299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3652-6846ed5490d7356a7d31ff216112ac763d2f91a2679b8d39bb4c24573b2203173</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EotPChgdAXrFApPUljhN21dAZKkYUFRBLy4lPWkNu-DLtPApvi8MMIDasLMvf__lcEHpGySklhJ1NbvSnjFDKHqAFJZXMCMnFQ7QgTJIsp1weoWPvvxKScMIeoyMqeFmVNF-gH-dDsENsOtAO6xhGne71aCx4bAc8q4MOgBs9NOBe48u-j4MNOxxGvLl4s16dTVK8whr76LZ2q7s5EiBFb-3NbbfDcD858B7MP7oQ-9F5rAeD56-36dlEZ4cbrKdxCqO3_gl61OrOw9PDeYI-ry4-Ld9mm6v15fJ8kzW8ECwryrwAI_KKGMlFoaXhtG0ZLdI4dCMLblhbUc0KWdWl4VVd5w3LheQ1Y4RTyU_Qi703Ffc9gg-qt76BrtMDjNGrQjIhWFUl8OUebFIX3kGrJmd77XaKEjUvQs3tqV-LSPDzgzXWPZi_6GHyCaB74M52sPuPSn24vvr4W5rtM9YHuP-T0e5bqpJLob68X6vy3XpJr9lKSf4T352kTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67255299</pqid></control><display><type>article</type><title>Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Daniels, Tracy ; Zhang, Jianying ; Gutierrez, Israel ; Elliot, Max L. ; Yamada, Brian ; Heeb, Mary Jo ; Sheets, Shaun M. ; Wu, Xiwei ; Casiano, Carlos A.</creator><creatorcontrib>Daniels, Tracy ; Zhang, Jianying ; Gutierrez, Israel ; Elliot, Max L. ; Yamada, Brian ; Heeb, Mary Jo ; Sheets, Shaun M. ; Wu, Xiwei ; Casiano, Carlos A.</creatorcontrib><description>BACKGROUND
Cancer patients produce autoantibodies to self‐proteins called tumor‐associated antigens (TAA). These autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. This study was designed to identify TAA in prostate cancer (PCa).
METHODS
Serum autoantibodies to the survival protein lens epithelium‐derived growth factor p75 (LEDGF/p75) were detected by immunofluorescence microscopy, ELISA, and immunoblotting. Expression of LEDGF/p75 in prostate cells and tumors was evaluated by immunoblotting or immunohistochemistry. Apoptotic cleavage of LEDGF/p75 was detected by immunoblotting.
RESULTS
Anti‐LEDGF/p75 autoantibodies were detected by ELISA in 18.4% of PCa patients and 5.5% of matched controls (P < 0.001) but not in patients with benign prostatic hyperplasia (BPH). LEDGF/p75 expression was detected in 93% of prostate tumors but not in normal prostate. Strong expression of the protein was observed in 61% of prostate tumors. Moderate to high expression was also detected in BPH tissue. Cleavage of LEDGF/p75 was detected in apoptotic prostate cells.
CONCLUSIONS
The high expression of LEDGF/p75 in prostate tumors and BPH could be induced by inflammation and oxidative stress. LEDGF/p75 cleavage fragments generated during prostate tumor cell death might trigger autoantibodies under inflammatory conditions in certain patients. © 2004 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20112</identifier><identifier>PMID: 15389814</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - immunology ; Adenocarcinoma - pathology ; Aged ; Aged, 80 and over ; Antibodies, Antinuclear - immunology ; Antigens, Neoplasm - immunology ; apoptosis ; Apoptosis - immunology ; autoantibodies ; Autoantibodies - immunology ; Biomarkers, Tumor - immunology ; Cell Line, Tumor ; Humans ; inflammation ; Intercellular Signaling Peptides and Proteins - immunology ; LEDGF/p75 ; Male ; Middle Aged ; oxidative stress ; prostate cancer ; Prostatic Neoplasms - immunology ; Prostatic Neoplasms - pathology ; Rhabdomyosarcoma, Embryonal - immunology ; tumor-associated antigens</subject><ispartof>The Prostate, 2005-01, Vol.62 (1), p.14-26</ispartof><rights>Copyright © 2004 Wiley‐Liss, Inc.</rights><rights>Copyright 2004 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3652-6846ed5490d7356a7d31ff216112ac763d2f91a2679b8d39bb4c24573b2203173</citedby><cites>FETCH-LOGICAL-c3652-6846ed5490d7356a7d31ff216112ac763d2f91a2679b8d39bb4c24573b2203173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.20112$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.20112$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15389814$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daniels, Tracy</creatorcontrib><creatorcontrib>Zhang, Jianying</creatorcontrib><creatorcontrib>Gutierrez, Israel</creatorcontrib><creatorcontrib>Elliot, Max L.</creatorcontrib><creatorcontrib>Yamada, Brian</creatorcontrib><creatorcontrib>Heeb, Mary Jo</creatorcontrib><creatorcontrib>Sheets, Shaun M.</creatorcontrib><creatorcontrib>Wu, Xiwei</creatorcontrib><creatorcontrib>Casiano, Carlos A.</creatorcontrib><title>Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
Cancer patients produce autoantibodies to self‐proteins called tumor‐associated antigens (TAA). These autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. This study was designed to identify TAA in prostate cancer (PCa).
METHODS
Serum autoantibodies to the survival protein lens epithelium‐derived growth factor p75 (LEDGF/p75) were detected by immunofluorescence microscopy, ELISA, and immunoblotting. Expression of LEDGF/p75 in prostate cells and tumors was evaluated by immunoblotting or immunohistochemistry. Apoptotic cleavage of LEDGF/p75 was detected by immunoblotting.
RESULTS
Anti‐LEDGF/p75 autoantibodies were detected by ELISA in 18.4% of PCa patients and 5.5% of matched controls (P < 0.001) but not in patients with benign prostatic hyperplasia (BPH). LEDGF/p75 expression was detected in 93% of prostate tumors but not in normal prostate. Strong expression of the protein was observed in 61% of prostate tumors. Moderate to high expression was also detected in BPH tissue. Cleavage of LEDGF/p75 was detected in apoptotic prostate cells.
CONCLUSIONS
The high expression of LEDGF/p75 in prostate tumors and BPH could be induced by inflammation and oxidative stress. LEDGF/p75 cleavage fragments generated during prostate tumor cell death might trigger autoantibodies under inflammatory conditions in certain patients. © 2004 Wiley‐Liss, Inc.</description><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - pathology</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Antinuclear - immunology</subject><subject>Antigens, Neoplasm - immunology</subject><subject>apoptosis</subject><subject>Apoptosis - immunology</subject><subject>autoantibodies</subject><subject>Autoantibodies - immunology</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Cell Line, Tumor</subject><subject>Humans</subject><subject>inflammation</subject><subject>Intercellular Signaling Peptides and Proteins - immunology</subject><subject>LEDGF/p75</subject><subject>Male</subject><subject>Middle Aged</subject><subject>oxidative stress</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - immunology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Rhabdomyosarcoma, Embryonal - immunology</subject><subject>tumor-associated antigens</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0EotPChgdAXrFApPUljhN21dAZKkYUFRBLy4lPWkNu-DLtPApvi8MMIDasLMvf__lcEHpGySklhJ1NbvSnjFDKHqAFJZXMCMnFQ7QgTJIsp1weoWPvvxKScMIeoyMqeFmVNF-gH-dDsENsOtAO6xhGne71aCx4bAc8q4MOgBs9NOBe48u-j4MNOxxGvLl4s16dTVK8whr76LZ2q7s5EiBFb-3NbbfDcD858B7MP7oQ-9F5rAeD56-36dlEZ4cbrKdxCqO3_gl61OrOw9PDeYI-ry4-Ld9mm6v15fJ8kzW8ECwryrwAI_KKGMlFoaXhtG0ZLdI4dCMLblhbUc0KWdWl4VVd5w3LheQ1Y4RTyU_Qi703Ffc9gg-qt76BrtMDjNGrQjIhWFUl8OUebFIX3kGrJmd77XaKEjUvQs3tqV-LSPDzgzXWPZi_6GHyCaB74M52sPuPSn24vvr4W5rtM9YHuP-T0e5bqpJLob68X6vy3XpJr9lKSf4T352kTw</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Daniels, Tracy</creator><creator>Zhang, Jianying</creator><creator>Gutierrez, Israel</creator><creator>Elliot, Max L.</creator><creator>Yamada, Brian</creator><creator>Heeb, Mary Jo</creator><creator>Sheets, Shaun M.</creator><creator>Wu, Xiwei</creator><creator>Casiano, Carlos A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis</title><author>Daniels, Tracy ; Zhang, Jianying ; Gutierrez, Israel ; Elliot, Max L. ; Yamada, Brian ; Heeb, Mary Jo ; Sheets, Shaun M. ; Wu, Xiwei ; Casiano, Carlos A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3652-6846ed5490d7356a7d31ff216112ac763d2f91a2679b8d39bb4c24573b2203173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - pathology</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Antinuclear - immunology</topic><topic>Antigens, Neoplasm - immunology</topic><topic>apoptosis</topic><topic>Apoptosis - immunology</topic><topic>autoantibodies</topic><topic>Autoantibodies - immunology</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Cell Line, Tumor</topic><topic>Humans</topic><topic>inflammation</topic><topic>Intercellular Signaling Peptides and Proteins - immunology</topic><topic>LEDGF/p75</topic><topic>Male</topic><topic>Middle Aged</topic><topic>oxidative stress</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - immunology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Rhabdomyosarcoma, Embryonal - immunology</topic><topic>tumor-associated antigens</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daniels, Tracy</creatorcontrib><creatorcontrib>Zhang, Jianying</creatorcontrib><creatorcontrib>Gutierrez, Israel</creatorcontrib><creatorcontrib>Elliot, Max L.</creatorcontrib><creatorcontrib>Yamada, Brian</creatorcontrib><creatorcontrib>Heeb, Mary Jo</creatorcontrib><creatorcontrib>Sheets, Shaun M.</creatorcontrib><creatorcontrib>Wu, Xiwei</creatorcontrib><creatorcontrib>Casiano, Carlos A.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daniels, Tracy</au><au>Zhang, Jianying</au><au>Gutierrez, Israel</au><au>Elliot, Max L.</au><au>Yamada, Brian</au><au>Heeb, Mary Jo</au><au>Sheets, Shaun M.</au><au>Wu, Xiwei</au><au>Casiano, Carlos A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>62</volume><issue>1</issue><spage>14</spage><epage>26</epage><pages>14-26</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><abstract>BACKGROUND
Cancer patients produce autoantibodies to self‐proteins called tumor‐associated antigens (TAA). These autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. This study was designed to identify TAA in prostate cancer (PCa).
METHODS
Serum autoantibodies to the survival protein lens epithelium‐derived growth factor p75 (LEDGF/p75) were detected by immunofluorescence microscopy, ELISA, and immunoblotting. Expression of LEDGF/p75 in prostate cells and tumors was evaluated by immunoblotting or immunohistochemistry. Apoptotic cleavage of LEDGF/p75 was detected by immunoblotting.
RESULTS
Anti‐LEDGF/p75 autoantibodies were detected by ELISA in 18.4% of PCa patients and 5.5% of matched controls (P < 0.001) but not in patients with benign prostatic hyperplasia (BPH). LEDGF/p75 expression was detected in 93% of prostate tumors but not in normal prostate. Strong expression of the protein was observed in 61% of prostate tumors. Moderate to high expression was also detected in BPH tissue. Cleavage of LEDGF/p75 was detected in apoptotic prostate cells.
CONCLUSIONS
The high expression of LEDGF/p75 in prostate tumors and BPH could be induced by inflammation and oxidative stress. LEDGF/p75 cleavage fragments generated during prostate tumor cell death might trigger autoantibodies under inflammatory conditions in certain patients. © 2004 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15389814</pmid><doi>10.1002/pros.20112</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2005-01, Vol.62 (1), p.14-26 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67255299 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenocarcinoma - immunology Adenocarcinoma - pathology Aged Aged, 80 and over Antibodies, Antinuclear - immunology Antigens, Neoplasm - immunology apoptosis Apoptosis - immunology autoantibodies Autoantibodies - immunology Biomarkers, Tumor - immunology Cell Line, Tumor Humans inflammation Intercellular Signaling Peptides and Proteins - immunology LEDGF/p75 Male Middle Aged oxidative stress prostate cancer Prostatic Neoplasms - immunology Prostatic Neoplasms - pathology Rhabdomyosarcoma, Embryonal - immunology tumor-associated antigens |
| title | Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T19%3A02%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antinuclear%20autoantibodies%20in%20prostate%20cancer:%20Immunity%20to%20LEDGF/p75,%20a%20survival%20protein%20highly%20expressed%20in%20prostate%20tumors%20and%20cleaved%20during%20apoptosis&rft.jtitle=The%20Prostate&rft.au=Daniels,%20Tracy&rft.date=2005-01-01&rft.volume=62&rft.issue=1&rft.spage=14&rft.epage=26&rft.pages=14-26&rft.issn=0270-4137&rft.eissn=1097-0045&rft_id=info:doi/10.1002/pros.20112&rft_dat=%3Cproquest_cross%3E67255299%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67255299&rft_id=info:pmid/15389814&rfr_iscdi=true |